Compare · ADMA vs GILD
ADMA vs GILD
Side-by-side comparison of ADMA Biologics Inc (ADMA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $159.05B, about 84.9x ADMA ($1.87B).
- Over the past year, ADMA is down 61.4% and GILD is up 13.4% - GILD leads by 74.8 points.
- GILD has been more active in the news (20 items in the past 4 weeks vs 2 for ADMA).
- GILD has more recent analyst coverage (25 ratings vs 9 for ADMA).
- Company
- ADMA Biologics Inc
- Gilead Sciences Inc.
- Price
- $8.05+1.07%
- $128.17-0.64%
- Market cap
- $1.87B
- $159.05B
- 1M return
- -4.84%
- -4.49%
- 1Y return
- -61.39%
- +13.44%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 2
- 20
- Recent ratings
- 9
- 25
ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ADMA
- ADMA Biologics Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Grossman Jerrold B bought $50,624 worth of shares (6,400 units at $7.91), increasing direct ownership by 1% to 520,284 units (SEC Form 4)
- Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 2% to 513,884 units (SEC Form 4)
- Director Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 3% to 501,384 units (SEC Form 4)
- SEC Form 10-Q filed by ADMA Biologics Inc
- ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
- ADMA Biologics Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
- ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors